---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-118565"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T21:08:49.299411+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# TransCode Q3 operating loss widens to $4.95M; cash $8.8M, runway through Q1 2023

## Summary
- Q3 operating loss $4.95M vs $2.36M in prior year; R&D expense $3.0M, up from $993K.
- Cash $8.8M at Sept 30 (down from $20.8M); plus ~$928K SBIR grant; expects to fund only through Q1 2023.
- Submitted eIND for Phase 0 trial of lead candidate TTX-MC138; reported preclinical efficacy in pancreatic cancer models.
- FDA granted orphan drug designation for TTX-siPDL1 in pancreatic cancer; strategic alliance with MD Anderson announced.

## SEC filing metadata
- accession: 0001104659-22-118565
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/0001104659-22-118565-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/tm2230414d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-118565
- JSON: https://secwatch.observer/filing/0001104659-22-118565.json
- Plain text: https://secwatch.observer/filing/0001104659-22-118565.txt

## Key facts
- Earnings Releases
  Transcode Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 14, 2022, TransCode Therapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829635/000110465922118565/0001104659-22-118565-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.